| 000 | 01197 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517163309.0 | ||
| 264 | 0 | _c20171106 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1080/14656566.2017.1353078 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSeeberger, Lauren C | |
| 245 | 0 | 0 |
_aValbenazine for the treatment of tardive dyskinesia. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cAug 2017 |
||
| 300 |
_a1279-1287 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMental Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aTardive Dyskinesia _xchemically induced |
| 650 | 0 | 4 |
_aTetrabenazine _xanalogs & derivatives |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aVesicular Monoamine Transport Proteins _xantagonists & inhibitors |
| 700 | 1 | _aHauser, Robert A | |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 18 _gno. 12 _gp. 1279-1287 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14656566.2017.1353078 _zAvailable from publisher's website |
| 999 |
_c27360104 _d27360104 |
||